HEALTH
1 min
– –
–
Roche claimed on Monday the success of two advanced clinical studies evaluating faricimab for the treatment of age-related neovascular (wet) macular degeneration. The laboratory assures that it has not observed any inferiority of its drug compared to aflibercept, despite an interval between injections of up to 16 weeks instead of eight for the Regeneron product.
–
–
–
– –
This advantage in terms of patient comfort was accompanied by an absence of unexpected adverse side effects, a press release said.
Age-related neovascular macular degeneration is considered the leading cause of blindness in people over the age of sixty.
The Rhine multinational intends to present the detailed results of the Tenaya and Lucerne studies, as well as those of the Yosemite and Rhine sections which focused on diabetic macular edema, at a forthcoming medical congress. They will also be submitted to health authorities around the world for approval.
Olav Zilian, of Mirabaud Securities, recalls betting on a maximum turnover of 2.5 billion francs by 2029, assuming that faricimab will replace Roche’s therapeutic options in the field.
At Vontobel, Stefan Schneider figures this potential in the only indication for age-related neovascular macular neurodegeneration at 400 million per year.
In another register, the pharmaceutical and diagnostic devices giant announced the signing in mid-December of a new global partnership agreement with Sysmex for the distribution of the hematological analyzers of the Japanese firm.
At 10:09 am, the Roche profit-sharing certificate was awarded 1.0% to 321.55 francs, at the top of an SMI up 0.62%.
– .
